 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. NASDAQ: INFI, a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, which addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Tuesday, November 2nd 2021, at 4:30pm ET to report its financial results for the third quarter of 2021. Conference call Webcast Details Date: 